DOT1L inhibitors have also been found to synergize with MI-2-2, MI-503, and VTP50469 in MLLr and NPM1 mutant leukemias [180,198,199,200], with combination treatment resulting in a more significant increase in differentiation compared to MI alone [180,198]. The gene discussed is DOT1L; the disease is leukemia.